Business
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“H
About this update from Tectonic Therapeutic, Inc.
[{"type":"image","alt":"Tectonic Therapeutic","displaySize":"","headline":null,"caption":"Tectonic Therapeutic","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/09e29d13a5147d733b1f52191d8f4124"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/23AfX4_2qGPR9uUgIzr4Uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/09e29d13a5147d733b1f52191d8f4124","width":300,"height":81}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)","length":245,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“HFrEF”) in March 2025","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents of $141.2 million as of December 31, 2024 and February 2025 private placement gross proceeds of approximately $185.0 million, together expected to provide a cash runway into Q4’28","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":725,"olType":false},{"type":"text","content":"WATERTOWN, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent business highlights.","length":453,"tagName":"p"},{"type":"text","content":"“2024 was an important year for Tectonic as we transitioned to a public company, and 2025 is already off to an excellent start,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic. “We are very pleased to have recently repor...